Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515
http://lobbyingdisclosure.house.gov

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510
http://www.senate.gov/lobby

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) **- All Filers Are Required to Complete This Page**

1. Registrant Name ☑ Organization/Lobbying Firm ☐ Self Employed Individual

HOGAN & HARTSON LLP

2. Address ☐ **Check if different than previously reported**

Address1 COLUMBIA SQUARE Address2 555 THIRTEENTH STREET NW

City WASHINGTON State DC Zip Code 20004 - Country USA

3. Principal place of business (if different than line 2)

City State Zip Code - Country

4a. Contact Name: Bultena, Lance D.

b. Telephone Number ☐ International Number: (202) 637-5600

c. E-mail: ldbultena@hhlaw.com

5. Senate ID#: 18422-1001525

7. Client Name ☐ *Self* ☐ *Check if client is a state or local government or instrumentality*

Agennix, Inc.

6. House ID#: 304700478

TYPE OF REPORT 8. Year 2008 Q1 (1/1 - 3/31) ☐ Q2 (4/1 - 6/30) ☐ Q3 (7/1-9/30) ☑ Q4 (10/1 - 12/31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ Termination Date _____ 11. No Lobbying Issue Activity ☐

INCOME OR EXPENSES **- YOU MUST complete either Line 12 or Line 13**

12. Lobbying

INCOME relating to lobbying activities for this reporting period was:

Less than $5,000 ☐

$5,000 or more ☑ $ $ 10,000.00

Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSE relating to lobbying activities for this reporting period were:

Less than $5,000 ☐

$5,000 or more ☐ $ _____

14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.

☐ **Method A.** Reporting amounts using LDA definitions only

☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Signature Filed Electronically **Date** 10/20/2008

Printed Name and Title Bultena, Lance D., Partner

v6.0.1f

Registrant HOGAN & HARTSON LLP Client Name Agennix, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FOO FOOD INDUSTRY (SAFETY, LABELING, ETC.) (one per page)

16. Specific lobbying issues

Followed implementation of the Food & Drug Administration Amendments Act of 2007, especially Section 912.

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Joseph A.	Levitt			☐
Lance D.	Bultena			☐
Gwen E.	Mellor			☐
Michael J.	Bell			☐
				☐
				☐
				☐
				☐
				☐

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

None

Printed Name and Title Bultena, Lance D., Partner

Registrant HOGAN & HARTSON LLP Client Name Agennix, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR HEALTH ISSUES (one per page)

16. Specific lobbying issues

Followed implementation of the Food & Drug Administration Amendments Act of 2007, especially Section 912.

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Joseph A.	Levitt			☐
Lance D.	Bultena			☐
Gwen E.	Mellor			☐
Michael J.	Bell			☐
				☐
				☐
				☐
				☐
				☐

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

None

Printed Name and Title Bultena, Lance D., Partner